This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
LAZCLUZE® (lazertinib)
Medical Information
Use of LAZCLUZE in Pediatric Patients
Last Updated: 08/21/2025
SUMMARY
- LAZCLUZE (lazertinib) is a kinase inhibitor indicated in combination with RYBREVANT (amivantamab-vmjw) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (Exon19del) or Exon 21 L858R substitution mutations, as detected by a United States Food and Drug Administration (FDA)-approved test.1
- The safety and effectiveness of LAZCLUZE in pediatric patients have not been established.1
- Please refer to LAZCLUZE product labeling for additional information.1
PRODUCT LABELING
- LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.
- RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
LITERATURE SEARCH
A literature search of MEDLINE®
References
| 1 | LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf |
Would you like to clear and leave your conversation? Message history will be lost.